Research-use information only. This article summarises published laboratory findings on AOD-9604. It is not a licensed medicine in the UK, is not approved for human consumption, and nothing here is medical or dosing advice.
AOD-9604 occupies an unusual corner of peptide research: it was engineered from a specific fragment of the growth-hormone molecule in an attempt to isolate one property — fat metabolism — from all the others. That design intent is what makes it a recurring subject in metabolic-research discussions, and search interest in its dosing, benefits and safety has grown steadily. This guide covers what the fragment actually is, how it is described to work, and the sourcing questions that matter for UK laboratory use.
What AOD-9604 is
AOD-9604 (Anti-Obesity Drug 9604) is a modified peptide fragment corresponding to the C-terminal region of human growth hormone — specifically the amino-acid 176–191 sequence — with a tyrosine modification added for stability. The rationale behind it is elegant: researchers had identified that the fat-metabolising activity of growth hormone appeared to reside in this small tail region, separate from the parts responsible for growth and glucose effects. AOD-9604 was created to reproduce that lipolytic signal without the full hormone’s wider actions.
How AOD-9604 is described to work
The mechanism reported in the literature is that AOD-9604 stimulates lipolysis (the breakdown of stored fat) and inhibits lipogenesis (the formation of new fat), apparently by acting on beta-3 adrenergic pathways in adipose tissue. Crucially, and unlike full growth hormone, the reported data suggest it does this without raising IGF-1 or meaningfully affecting blood glucose — the feature that generated the original interest. It is described as targeting the fat-handling machinery directly rather than working through the growth-hormone axis, which is why it is studied separately from secretagogues such as CJC-1295 or Ipamorelin.
Benefits reported in research
The reported research interest is narrower and more focused than for many peptides, which is arguably a strength:
- Fat metabolism. The core finding — increased lipolysis and reduced lipogenesis in adipose models — is the reason the compound exists.
- Metabolic selectivity. Reported data indicate it does not raise IGF-1 or disturb glucose the way exogenous growth hormone can, a distinguishing safety-relevant feature in study discussions.
- Cartilage and connective-tissue research. A secondary strand of literature has examined AOD-9604 in joint and cartilage-repair models, often alongside other regenerative peptides.
As with the wider category, the caveat holds: human clinical evidence is limited, and several of the most-quoted metabolic effects come from animal and early-phase work rather than large trials.
How dosing is described in the literature
Research documentation typically describes AOD-9604 in microgram-to-low-milligram quantities reconstituted in bacteriostatic water, referenced on a daily cadence in study protocols — frequently modelled in a fasted state, since the presence of food and elevated insulin is described as blunting lipolytic signalling. A “dosing chart” and “dosage calculator” are among the most common AOD-9604 searches because the microgram maths trips people up. These figures describe laboratory documentation, not human-use instructions. For the arithmetic of reconstitution and concentration, use our peptide reconstitution guide.
Side effects reported in research
AOD-9604’s reported profile is one of the milder ones in the fat-metabolism category, which follows from its selectivity. Observations centre on injection-site reactions and occasional transient headache or fatigue. Because it is reported not to elevate IGF-1 or disturb glucose appreciably, the metabolic-monitoring burden described in the literature is lighter than for full growth-hormone approaches. This describes research observations, not an established human safety profile.
The UK regulatory picture and sourcing
AOD-9604 is not a licensed medicine in the UK and is not approved for human consumption; legitimate supply is for laboratory research only. Its value depends entirely on being the correct fragment at genuine purity, so third-party HPLC verification, mass-spectrometry identity confirmation and a batch-specific Certificate of Analysis are non-negotiable. Our UK sourcing and due-diligence guide sets out what a real COA looks like.
Frequently asked questions
What are the benefits of AOD-9604?
Research associates AOD-9604 with increased fat breakdown and reduced fat formation, apparently without raising IGF-1 or disturbing glucose. A secondary literature examines cartilage-repair models. Most evidence is pre-clinical.
What is the dosage of AOD-9604?
Study protocols describe microgram-to-low-milligram amounts reconstituted in bacteriostatic water on a daily schedule, often modelled fasted. This describes research documentation, not a human dosing recommendation.
What are the side effects of AOD-9604?
Reported effects are generally mild — mainly injection-site reactions and occasional transient headache or fatigue — consistent with its selective, non-IGF-1-raising profile.
How is AOD-9604 different from growth hormone?
It reproduces only the fat-metabolising fragment of growth hormone (residues 176–191) and is reported to act on adipose tissue directly, without the growth and glucose effects of the full hormone.
Is AOD-9604 legal in the UK?
It is not a licensed medicine in the UK. Supply for human use without MHRA authorisation is unlawful under the Human Medicines Regulations 2012; supply for laboratory research is a separate, lawful category when correctly labelled.
Related research reading: AOD-9604 UK complete research guide · Research peptides explained.
